Research: An Alternative Approach to Asthma

It is estimated that asthma and other allergic diseases affect 20% of the world’s population. The number of sufferers in the United States exceeds 15 million. In the last 20 years, the number of asthma hospitalizations has increased by 50%. In the past ten years the number of asthma death cases has doubled! Dr. Ilan Zamir, one of the pioneers of homeopathy in Israel, has recently reported successful treatment of asthmatic patients with his own homeopathic methods.

Asthma is on the rise. Eight years ago, it was determined that 10% of all new IDF (Israeli Defence Forces) recruits had suffered from asthma at some time in the past, while 6% were current asthma sufferers.

Asthma, shortness of breath and spastic bronchitis are basically the same phenomenon, caused by the sensitivity and super-reaction of the respiratory system, leading to the contraction of the system muscle from any small irritation. In addition, at the time of the spasm of contractions, inflammatory cells are detected in the respiratory system. Some physicians believe that these are responsible for the spasms, coming out in a form of coarseness, whistles, cough and lack of breath – which can lead to death by asphyxia.

Environmental pollution agents, such as household dust, which increase the presence microscopic insects living in bed linen and in other parts of the house, only aggravate the problem, as do the presence of cockroaches, pets, and smoking (including passive smoking). High humidity and sport activities which dry out the respiratory system also serve to aggravate the problem. Mental and psychological stress may also exacerbate asthma symptoms.
Conventional treatment consists of medication to expand the bronchi by means of inhalation or swallowing, imitating the effect of adrenalin in the body. In severe cases, medicines containing steroids are given as preventive treatment to break down the inflammatory process. The generally accepted opinion is, however, that there is no known cure for asthma.

According to Dr. llan Zamir, the basic problem in dealing with asthma is that it almost always starts after an infectious disease, such as ear or throat infections or bronchitis, for which the patient is prescribed antibiotics. (continue)

FDA Probing Possible Link Between Asthma Drug and Suicide Risk

FDA is investigating a possible association between the use of Singulair and behavior/mood changes, suicidality (suicidal thinking and behavior) and suicide. Singulair is a medicine in the drug class known as leukotriene receptor antagonists. Singulair is used to treat asthma and the symptoms of allergic rhinitis (sneezing, stuffy nose, runny nose, itching of the nose) and to prevent exercise-induced asthma.

Over the past year, the maker of Singulair, Merck & Co, Inc., has updated the prescribing information and patient information for Singulair to include the following post-marketing adverse events: tremor (March 2007), depression (April 2007), suicidality (suicidal thinking and behavior) (October 2007), and anxiousness (February 2008).

In February 2008, FDA and Merck discussed how best to communicate these labeling changes to prescriber’s and patients. Merck plans to highlight the recent changes in the prescribing information in face-to-face interactions with prescriber’s and provide prescriber’s with patient information leaflets about Singulair. The Singulair website includes the most current prescribing information and patient information for Singulair (www.singulair.com).

FDA is working with Merck to further evaluate a possible link between the use of Singulair and behavior/mood changes, suicidality and suicide in response to inquiries received by FDA. FDA has requested that Merck evaluate Singulair study data for more information about suicidality and suicide. FDA is reviewing the postmarketing reports it has received of behavior/mood changes, suicidality and suicide in patients who took Singulair.

Due to the complexity of the analyses, FDA anticipates that it may take up to 9 months to complete the ongoing evaluations. As soon as this review is complete, FDA will communicate the conclusions and recommendations to the public.

Other leukotriene modifying medications include zafirlukast (Accolate), which is also a leukotriene receptor antagonist and zileuton (Zyflo and Zyflo CR), which is a leukotriene synthesis inhibitor. FDA is reviewing postmarketing reports it has received of behavior/mood changes, suicidality and suicide in patients who took Accolate, Zyflo, and Zyflo CR and will assess whether further investigation is warranted.

This early communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs.

The FDA urges both healthcare professionals and patients to report side effects from the use of Singulair, Accolate, Zyflo, and Zyflo CR to the FDA’s MedWatch Adverse Event Reporting program

Content Protected Using Blog Protector Plugin By: Make Money.

Optimized by SEO Ultimate